Karsen Perry A
SEC-identified person · CIK 1260573 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Lenz Therapeutics, Inc. LENZ | Director | filed 2021 - 2023 |
| Jounce Therapeutics, Inc. JNCE | Director | filed 2017 - 2023 |
| Intellia Therapeutics, Inc. NTLA | Director | filed 2016 - 2020 |
| Jiya Acquisition Corp. JYAC | Director | filed 2020 - 2020 |
| Voyager Therapeutics, Inc. VYGR | Director | filed 2015 - 2019 |
| Oncomed Pharmaceuticals Inc OMED | Director | filed 2016 - 2019 |
| Celgene Corp /DE/ CELG | see remarks | filed 2012 - 2016 |
| Neoprobe Corp NEOP | Director | filed 2014 - 2015 |
| Agios Pharmaceuticals, INC. AGIO | Director | filed 2013 - 2015 |
| Hepalife Technologies INC [ALQA] | Director | filed 2013 - 2013 |
| Stalar 3 Inc. N/A | Director · President | filed 2011 - 2011 |
| Stalar 4, Inc. N/A | Director · President | filed 2011 - 2011 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.